Pharma and tech are different industries. For example, tech benefits from network effects (if everyone uses LinkedIn it makes more sense to join), pharma doesn’t. In other words, tech scales. Could the massive success of GLP-1 drugs change this? Is the recent valuation of Eli Lilly at of $1 trillion a sign of things to come? Alex Telford considers this question here.
- Reblog
-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Nehaveigur 